Atara Biotherapeutics, Inc. announced initiation of two Phase 3 clinical studies to evaluate tabelecleucel (formerly known as ATA129) in patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD). Three clinical sites for both the MATCH and ALLELE pivotal studies are now open for enrollment in the U.S. and the studies will later expand to additional U.S. sites as well as sites in the EU, Canada and Australia. Tabelecleucel is Atara's off-the-shelf T-cell immunotherapy in development for the treatment of EBV+PTLD, as well as other EBV associated hematologic and solid tumors. Atara’s tabelecleucel Phase 3 program consists of two global, multicenter, open-label studies. For the treatment of patients with EBV+PTLD following allogeneic hematopoietic cell transplant (HCT) after failure of rituximab (MATCH), and for the treatment of patients with EBV+PTLD following solid organ transplant (SOT) after failure of rituximab or after failure of rituximab plus chemotherapy (ALLELE).